MedTrace Logo

Cubicin(R) for Complicated Post-surgical Wound Infections

NCT00651131 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-08-30

No results posted yet for this study

Summary

The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections

Conditions

  • Wound Infections

Interventions

DRUG

daptomycin

daptomycin i.v. 4 mg/kg q24h for 7-14 days

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-01
Primary Completion
2005-03-01
Completion
2005-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00651131 on ClinicalTrials.gov